Ovarian Endometrioid Adenocarcinoma Active Not Recruiting Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02923739Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment
NCT01097746First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerTreatment
NCT02853318Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment